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Hereditary angioedema 
type I in a female patient: 
a case report
ABSTRACT
Hereditary angioedema (HAE) is rare autosomal dominant disease, characterised by spontaneous and recurrent swellings 
in various parts of the body. The main inflammatory factor in HAE is bradykinin (a key mediator of non-allergic angioedema) 
and it is responsible for capillary leak. C1 esterase inhibitor (C1-INH) is a protease inhibitor that blocks the activation of the 
classic complement pathway, but there are also many others biochemical pathways, including kinin. Type I HAE is defined 
by low plasma levels of a normal C1 inhibitor (C1-INH).
Case presentation. A 34-year-old female patient presented to the hospital complained of swollen and painful legs, flatulence, 
palpebral and labial edema, dyspnea, dysuria, frequent herpetic infections of mouth and nose, subfebrile body temperature 
and was hoarse. Over the last 20 years she suffered from occasional edemas of the extremities and abdomen. Laboratory 
testing showed a reduced level of C1-INH, and with other test results normal we diagnosed the patient with HAE type I. For 
emergency situations, we prescribed icatibant (B2 bradykinin receptor antagonist) subcutaneously.
Individuals with HAE report episodic attacks during childhood that become more severe during adolescence. There is non-
pitting edema in 3 predisposed places : subcutaneous tissue, the abdomen and the larynx. Edemas amplify during 12-24 
hours and disappear during 3-5 days, with migrations to other locations. Treatment can be prophylactic, for acute attacks 
(icatibant) and before medical treatments. 
HAE is a potentially lethal disease and should be considered if repeating edema of various body parts, painful swelling and 
tightening of the skin are present. 
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Introduction
Hereditary angioedema (HAE) is an 
autosomal dominant inherited disea-
se, characterised by spontaneous and 
recurrent swelling of various parts of 
the body. (1) The exact prevalence is 
unknown, approximately 1 in 10,000 
people world-wide are affected. (2) 
There are 3 types of HAE. HAE type 
I has a decreased C1–INH level, and 
accounts for 85% of all HAE cases. 
HAE type II accounts for 15% of HAE 
cases and is caused by a normal or 
higher level of abnormal C1–INH. Type 
III is extremely rare and is not depen-
dant on C1–INH levels.
Diagnosis of that type is is made 
through genetic testing. C1–INH is a 
protease inhibitor, which blocks the 
activation of the classic complement 
pathway, fibrinolysis, but also many 
other biochemical pathways, including 
some parts of the kinin pathway. It is 
produced mainly by hepatocytes and 
marginally by monocytes. Androgens 
stimulate C1–INH production. As alre-
ady mentioned, bradykinin is conside-
red to be the main inflammatory factor 
in HAE. It is formed by action of the 
plasma enzyme kallikrein on substrate 
– kininogen. We consider it respon-
sible for capillary dilation and leak, 
smooth muscle relaxation, neutrophil 
chemotaxis. (3)
Case report
A 34-year-old female patient presen-
ted to the hospital complained of 
swollen and painful legs, flatulence, 
palpebral and labial edema, dyspnea, 
dysuria, frequent herpetic infections 
of mouth and nose, subfebrile body 
temperature and was hoarse. Over 
the last 20 years she suffered from 
occasional edemas of the extremiti-
es and abdomen, which significantly 
reduced her quality of her life.  She 
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has polycystic ovary syndrome (since 
2001) and Raynauld syndrome (since 
2010). Since 2007, she has had pro-
blems with rectorrhagy, flatulence, 
was febrile up to 41 °C (axillary) and 
has had daily variations in body mass 
of up to 5 kg. 
When admitted to hospital, her functi-
ons were stable. In clinical examination 
we found palpebral and labial edema, 
swollen legs and livedo reticularis on 
the lower extremities. We conducted 
laboratory tests for celiac disease, as 
well as tests for other immunological 
and endocrine diseases. These tests 
showed normal results, except for a 
lowered level of C1–INH (0.65, nor-
mal range 0.70-1.30). On the basis of 
these results, the patient was diagno-
sed with HAE type I.  For emergency 
situations, we prescribed icatibant 
(B2 bradykinin receptor antagonist) 
subcutaneously.
Discussion
Although rare, HAE is a potentially lethal 
disease. (3) HAE should be considered 
when angioedema is not followed by 
a rash, or when an attack does not 
respond to usual therapy. (1,3) In HAE 
cases, most of the laboratory results 
are within the normal range, as it was 
in this case. HAE treatment consists 
of prophylactic treatment, treatment of 
acute attacks and prophylactic trea-
tment prior to certain medical interven-
tions (dental procedures). Patients who 
suffered from a more severe attack, or if 
the attack affected the larynx, the head 
or the gastrointestinal system, must 
have medications for acute attacks 
nearby (bradykinin B2 receptor antago-
nist for subcutaneous treatment). (4) 
Long-term prophylaxis is provided in 
patients with frequent and/or severe 
attacks with weak androgens (danazol). 
With these patients, their liver function, 
full blood count, lipid profile and cardio-
vascular risk should be monitored.
Conclusion
HAE is under-diagnosed due to symp-
toms that are similar to other diseases 
and due to a lack of disease-awarene-
ss. Drugs for prevention and for trea-
tment of attacks should be available. 
Emergency centres should either be 
equipped with drugs, or they should be 
informed on where and how to obtain 
them in cases of emergency. 
